Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
Yejinpeng Wang,Liang Chen,Mengxue Yu,Yayun Fang,Kaiyu Qian,Gang Wang,Lingao Ju,Yu Xiao,Xinghuan Wang
DOI: https://doi.org/10.1002/cam4.3400
IF: 4.711
2020-08-25
Cancer Medicine
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>There is no good prognostic model that could predict the prognosis of bladder cancer (BCa) and the benefit of immunotherapy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Through the least absolute shrinkage and selection operator (LASSO) algorithm, we constructed a 13‐mRNA immune signature from the TCGA cohort (n = 406). We validated its prognostic value and predictive value for the benefit of immunotherapy with four independent validation cohort (<a class="linkBehavior" href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13507">GSE13507</a> [n = 256], <a class="linkBehavior" href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31684">GSE31684</a> [n = 93], <a class="linkBehavior" href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32894">GSE32894</a> [n = 308], and IMvigor210 cohort [n = 298]). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Our results indicating that high‐risk group with higher inhibitory immune cell infiltration (regulatory T cells [Tregs] and macrophage, etc), higher expression of immune checkpoints, and more T cell suppressive pathways (transforming growth factor β [TGF‐β], epithelial‐mesenchymal transition [EMT], etc) were activated. Besides, the immune signature showed a good predictive value for the benefit of immunotherapy in a cohort of urothelial carcinoma patients treated with PD‐L1.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The immune signature constructed is convenient to classify the immunotherapeutic susceptibility of patients with BCa, so as to achieve precision immunotherapy for BCa.</p></section>
oncology
What problem does this paper attempt to address?